Eledon Pharmaceuticals, Inc. ELDN
Set alert
2.77 USD -0.27 -8.88%
At close · Oct 30
2.93 +0.16 +5.68%
After hours · Oct 30, 7:57 PM ET
2.75 Day range 3.04
1.39 52-week range 4.36
- YTD
- +83.44%
- 1 year
- -36.32%
- Open
- 3.01
- Prev close
- 3.04
- Mkt cap
- 225.09M
- Vol
- 1.27M
- Avg vol
- 925.59K
- EPS
- -0.90
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.75
- High
- 3.04
- Forward P/E
- -3.49
- Beta
- 0.00
- Short ratio
- 0.75
- Inst. own
- 42.88%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.12
- 200-d avg
- 2.88
- 1y target
- 12.50
3M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 2, 2026 | 1 month ago |
| MACD: Sell Signal | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Sep 29, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| RSI: Oversold | Sep 9, 2026 | 1 month ago |
| RSI: Oversold | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
Key statistics
- Market cap
- 250.31M
- Enterprise value
- 182.77M
- Trailing P/E
- 5.74
- Forward P/E
- -3.49
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.27
- EPS (TTM)
- 0.73
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -23.20M
- Total cash
- 78.19M
- Total debt
- 501.00K
- Return on equity
- -25.36%
- Shares outstanding
- 59.74M
- Short % of float
- 1.29%
- 50-day average
- 4.12
- 200-day average
- 2.88
Analyst view
Consensus: none
Price target (mean) 12.50 +351.3% upside
Now 2.77
- Target (low)
- 7.00
- Target (mean)
- 12.50
- Target (high)
- 20.50
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.30333.
Financials — quick view
ELDN Revenue — quarterly 0
ELDN Net income — quarterly -31.63M
ELDN EPS — quarterly -0.27
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.30 | -0.32 | -0.02 | -6.67% |
| Aug 19, 2024 | Jun 1, 2024 | -0.31 | -0.32 | -0.01 | -3.23% |
| May 9, 2024 | Mar 1, 2024 | -0.37 | -0.34 | +0.03 | +8.11% |
| Mar 28, 2024 | Dec 1, 2023 | -0.38 | -0.29 | +0.09 | +23.68% |
| Nov 9, 2023 | Sep 1, 2023 | -0.41 | -0.35 | +0.06 | +14.63% |
| Aug 10, 2023 | Jun 1, 2023 | -0.47 | -0.40 | +0.07 | +14.89% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 7, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- eledon.com
News
- Eledon Pharma Reports Improved Quality Of Life And Reduced Symptom Burden With Tegoprubart In Kidney Transplant Patients At ASN Kidney Week 2026
- Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
- Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
- Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation Society
- Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026
- Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
- Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
- Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
- 647,812 Shares in Eledon Pharmaceuticals, Inc. $ELDN Acquired by ADAR1 Capital Management LLC
- Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate
Your note
Sign in to keep a note on ELDN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 8, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 10.53% | 6,293,282 | 26.37M | Sep 29, 2024 |
| Armistice Capital, LLC | 3.96% | 2,364,000 | 9.91M | Sep 29, 2024 |
| Vanguard Group Inc | 2.62% | 1,565,487 | 6.56M | Sep 29, 2024 |
| Schonfeld Strategic Advisors Llc | 2.51% | 1,500,000 | 6.29M | Sep 29, 2024 |
| Zimmer Partners, Lp | 2.40% | 1,434,727 | 6.01M | Sep 29, 2024 |
| Sphera Funds Management Ltd. | 2.17% | 1,297,321 | 5.44M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.93% | 1,152,398 | 4.83M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.64% | 385,138 | 1.61M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.37% | 220,431 | 923.61K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 87,894 | 368.27K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 56,617 | 237.22K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 48,878 | 204.80K | Oct 30, 2024 |